Title:
PREPARATION AND USE OF MACROCYCLIC HETEROCYCLIC COMPOUND AS EGFR INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2024/078263
Kind Code:
A1
Abstract:
The present invention relates to a macrocyclic heterocyclic compound as a selective inhibitor of a clinical mutant of EGFR kinase, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof, a stereoisomer thereof or a tautomer thereof, a preparation method therefor, a pharmaceutical composition containing same, and a medical use thereof.
Inventors:
LIANG YONGHONG (CN)
Application Number:
PCT/CN2023/119243
Publication Date:
April 18, 2024
Filing Date:
September 15, 2023
Export Citation:
Assignee:
YA THERAPEUTICS INC (CN)
International Classes:
C07D498/22; A61K31/439; A61P35/00; C07D487/04; C07D487/22
Domestic Patent References:
WO2022166741A1 | 2022-08-11 | |||
WO2009112439A1 | 2009-09-17 |
Foreign References:
CN114007698A | 2022-02-01 | |||
CN1675225A | 2005-09-28 | |||
CN113735856A | 2021-12-03 | |||
CN106164075A | 2016-11-23 | |||
CN114907379A | 2022-08-16 | |||
CN115073469A | 2022-09-20 |
Attorney, Agent or Firm:
SHENZHEN ANYMEN PATENT AGENCY (GENERAL PARTNERSHIP) 91440300MA5GNMBB68 et al. (CN)
Download PDF: